A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopietic Stem Cell Transplant
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Defibrotide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 23 Feb 2018 According to a Jazz Pharmaceuticals media release, first patient has been enrolled.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Jazz Pharmaceuticals media release.
- 06 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.